Latest news and articles about pharmaceutical industry from NEX English
The National Medical Products Administration in China has approved 19 innovative drugs, with 15 being locally developed. This marks a significant surge in the country's biotechnology sector.
Demis Hassabis, co-founder and CEO of Google's DeepMind, announced the launch of Isomorphic Labs. The company aims to leverage artificial intelligence technologies to accelerate the development of new drugs, marking a significant step in the biotechnology field.
CSL Ltd. has announced a reduction in its profit forecasts for the current financial year, citing additional losses estimated at around $5 billion. This decision follows a comprehensive review by the interim CEO, highlighting significant challenges facing the company.
Saba Pharmaceuticals announced that it expects to achieve profits of <strong>10 million pounds</strong> in <strong>2025</strong>, reflecting the success of its strategies to improve financial performance. This turnaround comes amid the challenging economic conditions faced by many companies in the market.
Minister of Industry, Eng. Khaled Hashem, held a meeting with the Pharmaceutical and Cosmetics Industry Chamber to discuss the challenges and needs for advancing the sector. Hashem emphasized the importance of encouraging companies to deepen the production of active pharmaceutical ingredients to position Egypt as a regional hub.
Nile Pharmaceuticals announced a net profit of <strong>239 million EGP</strong> for the nine months ending September 2023, reflecting the company's strong performance in the Egyptian market. This financial success highlights the company's ability to adapt to economic challenges and achieve sustainable growth in the pharmaceutical sector.
The General Assembly of GlaxoSmithKline recently approved a decision to purchase and retire several production lines, reflecting the company's commitment to enhancing its production capabilities and meeting market demands.
The General Assembly of GlaxoSmithKline has approved the distribution of a cash dividend to shareholders, alongside the purchase and retirement of new production lines. These measures aim to enhance the company's investments and expand its operations.
Atico Pharma Egypt is targeting sales of <strong>$10 million</strong> by the end of this year, representing a <strong>50%</strong> increase, according to CEO Waheed Atique. The company plans to boost its exports to <strong>$6 million</strong> by <strong>2026</strong>.
Jamjoom Pharmaceutical Company announced its intention to finalize the acquisition of the Pfizer factory within four months, contingent upon obtaining necessary regulatory approvals. This move is part of the company's strategy to enhance its production capacity.
The Indonesian Food and Drug Authority (BPOM) announced its support for enhancing the local pharmaceutical industry to reduce reliance on imports, which currently stands at 80%. This announcement was made during the opening of a new factory in Pasuruan.
LEO PHARMA A/S has unveiled its new plans to boost innovation in the pharmaceutical industry, aiming to expand its research and develop new products to meet increasing market demands. This announcement comes at a time of significant transformations in the healthcare sector.
Vas Narasimhan, CEO of Novartis, warns that the drug pricing policy established by President Trump will have negative repercussions for both pharmaceutical companies and patients. The effects of these policies are expected to manifest in the next eighteen months.
Sources indicate that the Italian company Angelini Pharma is exploring the possibility of acquiring the American company Catalyst Pharma. This move aims to expand its global operations and enhance its presence in international markets.
Global drug prices are experiencing a significant increase due to pressures from rising fuel and energy costs, exacerbated by the closure of the Strait of Hormuz. This situation negatively impacts manufacturing costs and supply chains, raising concerns among consumers and affected nations.
CVC Capital Partners is looking to gather investors to help finance its proposed acquisition of the Italian pharmaceutical company Recordati, valued at approximately <strong>€10.9 billion</strong> (around <strong>$12.7 billion</strong>). This move aims to enhance the company's competitive edge in the global pharmaceutical market.
Novo Nordisk's CEO revealed that the weight loss drug industry has only reached <strong>15%</strong> of potential customers, indicating significant untapped opportunities. This statement comes amid rising global demand for weight loss medications.
Insilico Medicine has announced a collaboration agreement with Eli Lilly worth <strong>$2.75 billion</strong> aimed at developing new drugs. This partnership comes at a time when the pharmaceutical industry is increasingly turning to modern technology for research and development.
Pharmaceutical companies in Germany and Switzerland have warned that new US tariffs on drug products pose a serious threat to production sites in Europe, raising concerns about the future of the industry.
German Pharmaceutical Association President Dorothea Brackmann has warned of potential drug shortages in Germany stemming from the ongoing conflict in Iran, highlighting the country's heavy reliance on imported raw materials from the region.
Eli Lilly's CEO, Dave Ricks, announced the company's opposition to the White House's efforts to legislate a 'most favored nation' policy for drug pricing. This comes as the U.S. administration seeks to affirm lower drug prices in the American market.
Fabros Pharmaceutical Company announced a net profit of <strong>27.44 billion Indonesian rupiah</strong> in 2025, recovering from a loss of <strong>290.63 billion rupiah</strong> the previous year. This positive turnaround is attributed to a <strong>26.34%</strong> increase in sales.
Eli Lilly, a leading American pharmaceutical company, has announced its acquisition of Synthego for <strong>$7.8 billion</strong>, marking its entry into the growing sleep disorder medication market. This strategic move aims to expand the company's portfolio and enhance its position in the pharmaceutical industry.
Biogen, a company specializing in drug development, has announced its acquisition of Apellis Pharmaceuticals for <strong>$5.6 billion</strong>. This move aims to expand Biogen's capabilities in treating kidney diseases, addressing the growing need for effective therapies.
Lilly, the American pharmaceutical giant, has announced its acquisition of a company specializing in the development of a drug for narcolepsy, in a deal valued at up to <strong>$7.8 billion</strong>. This move aims to expand the company's market presence and enhance its drug portfolio.
The Assistant Head of the Egyptian Drug Authority confirmed that the authority regularly monitors the manufacturing process, ensuring that the strategic drug stock remains stable despite industry challenges. This reflects the commitment to meet citizens' health needs.
Eli Lilly, a leading American pharmaceutical company, has announced a strategic deal worth up to <strong>$2.75 billion</strong> with Hong Kong-based Insilico Medicine to develop drugs discovered using <strong>artificial intelligence</strong>. The agreement includes an initial payment of <strong>$115 million</strong>, with potential additional earnings tied to regulatory and commercial milestones.
CVC Capital Partners plans to explore potential divestment options for the Italian pharmaceutical company Recourati following its successful acquisition for €10.9 billion. This move is part of CVC's strategy to enhance its investment portfolio.
Merck & Co. is in advanced talks to acquire Turners Pharmaceuticals, a move aimed at strengthening its portfolio of drugs and treatments. This acquisition reflects Merck's strategy to expand its presence in the global pharmaceutical market.